As the world's largest protein producer, JBS N.V. (JBS) manages a diversified portfolio that includes beef, pork, poultry, and processed foods across North America, Brazil, Australia, and Europe. After delivering record full-year 2025 revenue of $86 billion and net income of $2 billion, the upcoming Q1 2026 earnings report will provide insight into whether that momentum continues, particularly with tight U.S. cattle supplies and shifting global demand. From my perspective, this report is crucial for investors because it sheds light on operational efficiency, segment performance, and capital allocation decisions in a challenging commodity market. With shares trading near recent highs following the NYSE listing, the results could indicate if JBS can sustain its advantage across multiple proteins amid inflation and supply chain issues, which would also have implications for peers like Pilgrim's Pride.
Analysts are forecasting consensus revenue of $21.68 billion for Q1 2026 (January-March), a slight increase from prior periods, supported by volume growth in poultry and prepared foods that should offset headwinds in beef. The EPS consensus comes in at $0.24, with estimates ranging from $0.20 to $0.32—this follows Q4 2025's reported $0.39 against an expected $0.41. Key figures to watch include adjusted EBITDA, with margins projected around 7-8% in line with full-year trends, and leverage moving toward 2.5x or lower.
Looking back, the company has consistently beaten revenue expectations: Q4 2025 came in at $23.06 billion versus $22.6 billion anticipated (+15% YoY), and Q3 hit $22.6 billion (also a beat). EPS results have been more varied, with Q4 slightly missing the mark but full-year EPS rising 15% to $1.89. Stock reactions have been muted post-Q4 despite the revenue strength. I expect guidance to cover 2026 capex of $2.4 billion (split between expansion and maintenance) along with working capital requirements.
Investor sentiment heading into Q1 earnings feels cautiously optimistic. Recent analyst upgrades, such as Goldman Sachs' 'Buy' rating with a $48 price target, have pushed shares to 7-month highs. The overall consensus remains a Strong Buy, supported by the strong 2025 performance. That said, risks persist from tight U.S. beef supplies and elevated grain costs. Historically, beats have led to 5-10% upside, while misses could add pressure in this volatile environment. One thing that stands out to me is how resilient the stock has been amid these upgrades.
In reviewing JBS, I also checked this using Tickeron’s AI Screener, which helps me filter stocks and ETFs based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. It scans thousands of instruments with customizable filters like industry, market cap, technical indicators, price patterns, and performance metrics, making it easier to spot trade ideas, trending stocks, breakout candidates, and opportunities that might otherwise take hours to uncover manually. I find it particularly useful for comparing companies like JBS against sector peers efficiently.
Once earnings are out, attention will turn to reaffirmation of 2026 guidance. Management aims for EBITDA cash flow breakeven at $5.7 billion, factoring in $2.4 billion in capex and stable working capital—this should support free cash flow after 2025's $400 million generation.
Segment performance deserves close monitoring: Beef in North America continues to face cattle supply constraints into 2026, though exports from Australia and Brazil provide some balance. Upside potential lies in poultry (Pilgrim's Pride, Seara) and U.S. pork expansions, including new Iowa plants ramping up by 2027 to add $500-750 million in revenue at double-digit margins. Prepared foods have shown resilience with growth exceeding 25% in recent quarters.
Broader macro influences include commodity prices for grains and livestock, currency fluctuations (BRL/USD), and demand trends in China and the EU following reopenings. Leverage stood at 2.39x at Q4's end, providing room for buybacks and dividends ($1/share ex-May 18), with $7.4 billion in liquidity enabling opportunistic M&A. I'm watching Q2 trends closely as they will shape the full-year path toward revenue exceeding $88 billion.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
JBS saw its Momentum Indicator move above the 0 level on June 23, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned positive. In of the 95 cases, the stock moved higher in the following days. The odds of a move higher are at .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where JBS's RSI Indicator exited the oversold zone, of 21 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for JBS just turned positive on June 10, 2026. Looking at past instances where JBS's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where JBS advanced for three days, in of 288 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 65 cases where JBS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JBS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for JBS entered a downward trend on June 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.762) is normal, around the industry mean (4.730). P/E Ratio (7.358) is within average values for comparable stocks, (34.854). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.835). JBS has a moderately high Dividend Yield (0.113) as compared to the industry average of (0.063). P/S Ratio (0.145) is also within normal values, averaging (8.308).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. JBS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows